Nise pain relief tablet

''Nise'' tablet is a trademark for the drug ''Nimesulide'' which is non-steroidal anti-inflammatory drug (NSAID)
  with analgesic and antipyretic properties.

  It is used for the treatment of acute pain, Primary dysmennorhea and also to treat degenerative joint disease.

 Nimesulide drug was launched in Italy for the first time as Aulin and Mesulid in 1985 and is presently available     in more than 50 countries worldwide with different trademarks such as Nise, Sulide, Nimalox, Nimesil, Nimulid, Nicip, Nimcap, Sulidene, and Zolan etc.

It has superior gastrointestinal safety as compared to other NSAIDs.

Nise tablet also shows rapid analgesic activity which gives reductions for the pain within 15 minutes from drug intake.

It must be used under supervision by a doctor in accordance with the approved indications and in compliance with the recommendations.

 

Nise medicine has the rapid onset of analgesic action which shows the immediate relief within the 15 min from the drug intake for the acute pain.

Nise tablet for rapid onset analgesic action

Nise tablet is a prescribed Non-steroidal anti-inflammatory drug with multifactorial mode of action,characterized by a fast onset of analgesic activity. It’s one of the brand for the Nimesulide medicine.

It’s multifactorial mode of action gives the best results in the treatment of Acute (short term) pain, Painful osteoarthritis (Swelling in the joints) and Primary dysmennorhea ( Period Pains).

Clinical studies have been carried out in a wide variety of acute inflammatory and painful conditions with the aim of evaluating the analgesic activity of Nise.

These studies have proven that efficacy of Nise has a rapid pain relief with in the 15min from drug intake.

Nimesulide is a prescription-only drug and must be prescribed by a licensed physician after careful evaluation of the patient’s characteristics and needs. It is preffered to be used for the shortest duration.

prescribed painkiller drug-nimesulide

The most prescribed anti-inflamatory drug Nimesulide was first developed by Helsinn Healthcare and is marketed world-wide.

NImesulide is available in the form of tablets (100 mg), granules for oral suspension (100 mg), suppositories (200 mg) and gel (3%).

The anti-inflammatory drug mechanism of Nimesulide should only be prescribed as second line treatment. It provides the fast onset of the analgesic action.

The rapid onset of the analgesic action is crucial for the patients with acute pain and also in case of treatment with systemic NSAIDs

The harmonized indications in the EU are acute pain, primary dysmenorrhoea. The dosage of Nimesulide ought to be used is 100 mg twice daily, the duration prescribed is 15 days to minimize the risk of hepatotoxicity.

The drug must be used under supervision by a licensed physician in accordance with the approved indications. Prescription of the Nimesulide must be based on assessment of the patients’ characteristics and needs.

Nimesulide is contraindicated in children below 12 years and in patients suffering from liver problems.

Nimesulide efficay in pain

The abilities of NSAID’s drug nimesulide to inhibit COX-2 preferentially and to exert other novel anti-inflammatory actions are consistent with good efficacy and safety with highly effective in reducing pain, inflammation and also helps in better penetration of the antibiotics.

Nimesulide posses analgesic properties with multifactorial mode of action for the treatment of musculoskeletal system, dysmenorrhoea, and acute pain .

It also undergoes extensive biotransformation. The recent study on the basis of analgesic activity of nimesulide has proved that Nimesulide had a quicker onset which shows relief from pain relief and inflammation within 15 minutes from drug intake.

Nimesulide is recommended for the shortest duration necessary to control symptoms in patients with acute pain or primary dysmenorrhoea.

Nimesulide is available in distinctive brands, for instance, Sulide, Nimalox, Nimesil, Nimulid, Nicip, Nimcap, Nise, Sulidene, Zolan and etc.

Nimesulide tablet for cancer treatment

Cancer, also known as a malignant tumour or malignant neoplasm, is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Cyclooxygenase-2 (COX-2) inhibitor Nimesulide inhibits the proliferation of various types of cancer cells mainly via COX-2 independent mechanisms, which makes it a good lead compound for anti-cancer drug development.

There are more than 100 types of cancer, including breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. Symptoms vary depending on the type.

A series of new nimesulide analogs were synthesized based on the structure–function analysis generated previously. It displayed very potent anti-cancer activity.

significantly suppresses the growth of multiple cancer. By usng Nimesulide the sizes of the colon carcinomas were also decreased.

Pharmacokinetic studies demonstrate the good bioavailability of the compound. A set of non-COX-2 active Nimesulide anti-cancer derivatives were synthesized. It works as a good lead compound for anti-cancer drug development

Nimesulide granules

Nimesulide Granules is non-steroidal anti-inflammatory drugs, indicated for the treatment of juvenile chronic arthritis, postoperative pain, acute pain after trauma and primary dysmenorrhea.

Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties.

Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.

Active ingredients: nimodipine. Indication: nimesulide granules is non-steroidal anti-inflammatory drugs, indicated for the treatment of juvenile chronic arthritis, postoperative pain, acute pain after trauma and primary dysmenorrhea.

Packaging: 1g / sack; 6, 8, 10 sacks / pack. Contact us for more information.

usage and consumption: oral, the goods only for adults only, a 50 mg to 100 mg daily twice postprandial taking. In accordance with the severity of the conditions and the needs of the patients can be increased to 0.2g, the second service.

elderly patients of the medication should strictly comply with the provisions of doctors. Doctors can reduce under appropriate in the circumstances listed above dosage.